A full-cycle biopharmaceutical complex worth 103 billion tenge will be built in Kazakhstan

As part of the implementation of the instructions of the President of the Republic of Kazakhstan to increase the share of domestic production in the pharmaceutical industry to 50%, a major strategic investment project will be implemented in Kazakhstan. The corresponding resolution has been signed by Prime-minister Olzhas Bektenov.

The document approved the draft Investment Agreement between the Ministry of healthcare of the Republic of Kazakhstan and Khan Tengri Biopharma LLP for the construction of a modern manufacturing complex in the Alatau Special Economic Zone.

The total volume of investments will exceed 103 billion tenge, and the project will create more than 180 new permanent jobs.

The implementation of this project is of strategic importance for the development of Kazakhstan’s pharmaceutical industry and is aimed at expanding local production, forming a sustainable manufacturing base, and as well as phased import substitution of socially significant medicines. In addition, part of the output goods are planned for export to the markets of the EAEU, CIS, as well as countries of the Middle East.

Read more: https://primeminister.kz/en/news/full-cycle-biopharmaceutical-complex-worth-103-billion-teenge-to-be-built-in-kazakhstan-30918

Alatau city will receive a special status: a draft law has been developed

Previous article

Pet food manufacturing plant with investments exceeding 88 billion tenge will be built in the Almaty region

Next article